Skip to main content

Articles

Page 11 of 14

  1. Many patients even those with health insurance pay out-of-pocket for medicines. We investigated the availability and prices of essential medicines in the Boston area.

    Authors: Abhishek Sharma, Lindsey Rorden, Margaret Ewen and Richard Laing
    Citation: Journal of Pharmaceutical Policy and Practice 2016 9:12
    Content type: Research Published on:

  2. A wide range of pharmaceutical products are needed for diagnosis, treatment, and prevention of HIV/AIDS. However, interrupted supplies and stock-outs are the major challenges in the supply chain of ARV medicin...

    Authors: Eyerusalem Berhanemeskel, Gebremedhin Beedemariam and Teferi Gedif Fenta
    Citation: Journal of Pharmaceutical Policy and Practice 2016 9:11
    Content type: Research Published on:

  3. Antibiotic resistance is a serious global public health problem directly correlated to high antibiotic consumption. Romania is one of the European countries with the highest rates of antibiotic consumption, no...

    Authors: I. Ghiga and C. Stålsby Lundborg
    Citation: Journal of Pharmaceutical Policy and Practice 2016 9:10
    Content type: Research Published on:

  4. In October 2015, the third international Pharmaceutical Pricing and Reimbursement Information (PPRI) Conference was held in Vienna to foster discussion on challenges in pricing and reimbursement policies for m...

    Authors: Sabine Vogler, Nina Zimmermann, Alessandra Ferrario, Veronika J. Wirtz, Kees de Joncheere, Hanne Bak Pedersen, Guillaume Dedet, Valérie Paris, Aukje K. Mantel-Teeuwisse and Zaheer-Ud-Din Babar
    Citation: Journal of Pharmaceutical Policy and Practice 2016 9:9
    Content type: Editorial Published on:

  5. Financial recession mandated the introduction of harsh austerity measures. Health, and particularly pharmaceuticals, constitute a significant part of public expenditure and as such they have been subject to si...

    Authors: Panagiotis Petrou and Michael A. Talias
    Citation: Journal of Pharmaceutical Policy and Practice 2016 9:8
    Content type: Research Published on:

  6. Clinical pharmacy service has evolved steadily over the past few decades and is contributing to the ‘patient care journey’ at all stages. The service improves safety and effectiveness of medicines, thereby avo...

    Authors: Arebu Issa Bilal, Zelalem Tilahun, Gebremedhin Beedemariam, Belete Ayalneh, Bisrat Hailemeskel and Ephrem Engidawork
    Citation: Journal of Pharmaceutical Policy and Practice 2016 9:7
    Content type: Research Published on:

  7. Ghana established its National Health Insurance Scheme (NHIS) in 2003 with the goal of ensuring more equitable financing of health care to improve access to health services. This qualitative study examines the...

    Authors: Paul G. Ashigbie, Devine Azameti and Veronika J. Wirtz
    Citation: Journal of Pharmaceutical Policy and Practice 2016 9:6
    Content type: Research Published on:

  8. Clinical trials showed a higher risk of skin- and liver- related adverse reactions when NVP-based antiretroviral therapy (ART) was initiated in female and male patients with baseline CD4 cell counts ≥250 and ≥...

    Authors: Francis Kalemeera, Assegid T. Mengistu and Johannes Gaeseb
    Citation: Journal of Pharmaceutical Policy and Practice 2016 9:5
    Content type: Research Published on:

  9. Little is known about the perceived attitude, barriers and facilitators of Saudi Pharmacists about practice based research. We aimed to measure the attitude, barriers, and facilitators of Saudi hospital pharma...

    Authors: Khizra Sultana, Majed Al Jeraisy, Maha Al Ammari, Rahul Patel and Syed Tabish R. Zaidi
    Citation: Journal of Pharmaceutical Policy and Practice 2016 9:4
    Content type: Research Published on:

  10. This scoping review investigates the relationship between governance, pharmacovigilance, and Agencia Nacional de Vigilancia Sanitaria (ANVISA) in Brazil, which has authority over Brazil's national pharmaceutic...

    Authors: Kathy Moscou, Jillian C. Kohler and Anita MaGahan
    Citation: Journal of Pharmaceutical Policy and Practice 2016 9:3
    Content type: Research Published on:

  11. As medicines are becoming more targeted and complex in the U.S., ensuring patients’ safe use of medications with known dangerous risks is critical for public health and safety. Therefore, the Risk Evaluation a...

    Authors: Stacey L. Worthy
    Citation: Journal of Pharmaceutical Policy and Practice 2016 9:2
    Content type: Research Published on:

  12. The increasing prevalence of chronic diseases puts a high burden on the health care systems of Low and Middle Income Countries which are often not adapted to provide the care needed. Peer support programmes ar...

    Authors: Josefien van Olmen, Natalie Eggermont, Maurits van Pelt, Heang Hen, Jeroen de Man, François Schellevis, David H. Peters and Maryam Bigdeli
    Citation: Journal of Pharmaceutical Policy and Practice 2016 9:1
    Content type: Research Published on:

  13. Authors: Edmund Rutta, Jafary Liana, Martha Embrey, Keith Johnson, Suleiman Kimatta, Richard Valimba, Rachel Lieber, Elizabeth Shekalaghe and Hiiti Sillo
    Citation: Journal of Pharmaceutical Policy and Practice 2015 8:29
    Content type: Erratum Published on:

    The original article was published in Journal of Pharmaceutical Policy and Practice 2015 8:23

  14. The Nigerian health sector battles with control of infectious diseases and emerging non-communicable diseases. Number of healthcare personnel involved in public health programs need to be boosted to contain th...

    Authors: Ogochukwu Offu, Maureen Anetoh, Matthew Okonta and Obinna Ekwunife
    Citation: Journal of Pharmaceutical Policy and Practice 2015 8:27
    Content type: Research Published on:

  15. The irrational use of reserved antimicrobials, such as ceftriaxone, is one of the global public health issues particularly to low income countries like Ethiopia, leading to high costs of treatment or therapeut...

    Authors: Tariku Shimels, Arebu I Bilal and Anwar Mulugeta
    Citation: Journal of Pharmaceutical Policy and Practice 2015 8:26
    Content type: Research Published on:

  16. Some humanitarian and development organizations respond to major natural disasters and emergencies by donating medicines. Many provide medicines on a routine basis to support health systems, particularly those...

    Authors: Nuria Cañigueral-Vila, Jennifer C. Chen, Lindsey Frenkel-Rorden and Richard Laing
    Citation: Journal of Pharmaceutical Policy and Practice 2015 8:28
    Content type: Review Published on:

  17. Withdrawal of conditional regulatory approval or subsidization of new medicines when subsequent evidence does not confirm early trial results may not be well understood or accepted by the public.

    Authors: Agnes Vitry, Tuan Nguyen, Vikky Entwistle and Elizabeth Roughead
    Citation: Journal of Pharmaceutical Policy and Practice 2015 8:25
    Content type: Research Published on:

  18. Hypertension is the leading modifiable cause of mortality worldwide. Unlike many conditions where limited evidence exists for management of older individuals, multiple large, robust trials have provided a soli...

    Authors: Tariq M Alhawassi, Ines Krass and Lisa G Pont
    Citation: Journal of Pharmaceutical Policy and Practice 2015 8:24
    Content type: Review Published on:

  35. Authors: Roberta Joppi, Elisa Cinconze, Luca Demattè, Renato Guseo, Claudio Jommi, Cinzia Mortarino, Daniela Pase, Chiara Poggiani, Alessandro Roggeri and Daniela Roggeri
    Citation: Journal of Pharmaceutical Policy and Practice 2015 8(Suppl 1):P9
    Content type: Poster presentation Published on:

    This article is part of a Supplement: Volume 8 Supplement 1

Submit manuscript

Follow

Annual Journal Metrics

Journal of Pharmaceutical Policy and Practice

ISSN: 2052-3211

Contact us